GLP-1 Antibody (HYB 011-05): sc-57165
- GLP-1 Antibody (HYB 011-05) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against human GLP-1 peptide coupled to diphtheria toxoid with glutaraldehyde
- recommended for detection of GLP-1 of mouse, rat and human origin by IF; non cross-reactive with either activated forms GLP1 (7-36) amide or GLP1 (7-37) amide
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GLP-1 Antibody (HYB 011-05). This work is in progress.
GLP-1 Antibody (HYB 011-05) is a mouse monoclonal IgG1 antibody that detects glucagon-like peptide-1 (GLP-1) in mouse, rat, and human samples through immunofluorescence (IF) applications. GLP-1 plays a crucial role in glucose metabolism and appetite regulation, functioning as a key hormone in the endocrine system. GLP-1 is primarily secreted by intestinal L-cells in response to food intake, where GLP-1 enhances insulin secretion from the pancreas while simultaneously inhibiting glucagon release, thereby lowering blood sugar levels. This dual action not only helps maintain glucose homeostasis but also contributes to the sensation of satiety, making anti-GLP-1 antibody (HYB 011-05) a significant target for therapeutic interventions in conditions such as type 2 diabetes and obesity. GLP-1′s importance extends beyond metabolic functions, as GLP-1 also acts on the central nervous system to influence feeding behavior, highlighting GLP-1′s multifaceted role in both peripheral and central regulation of energy balance. With specificity and reliability, GLP-1 (HYB 011-05) antibody serves as an essential tool for researchers investigating physiological and pathological roles of GLP-1 in various biological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GLP-1 Antibody (HYB 011-05) References:
- GIP and GLP-1, the two incretin hormones: Similarities and differences. | Seino, Y., et al. 2010. J Diabetes Investig. 1: 8-23. PMID: 24843404
- Adverse Effects of GLP-1 Receptor Agonists. | Filippatos, TD., et al. 2014. Rev Diabet Stud. 11: 202-30. PMID: 26177483
- GLP-1 and weight loss: unraveling the diverse neural circuitry. | Kanoski, SE., et al. 2016. Am J Physiol Regul Integr Comp Physiol. 310: R885-95. PMID: 27030669
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. | Willard, FS., et al. 2020. JCI Insight. 5: PMID: 32730231
- Central and peripheral GLP-1 systems independently suppress eating. | Brierley, DI., et al. 2021. Nat Metab. 3: 258-273. PMID: 33589843
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. | Zhao, X., et al. 2021. Front Endocrinol (Lausanne). 12: 721135. PMID: 34497589
- GLP-1 physiology informs the pharmacotherapy of obesity. | Drucker, DJ. 2022. Mol Metab. 57: 101351. PMID: 34626851
- GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. | Moore, PW., et al. 2023. Adv Ther. 40: 723-742. PMID: 36566341
- GLP-1-directed NMDA receptor antagonism for obesity treatment. | Petersen, J., et al. 2024. Nature. 629: 1133-1141. PMID: 38750368
- GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. | Kim, KS., et al. 2024. Science. 385: 438-446. PMID: 38935778
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLP-1 Antibody (HYB 011-05) | sc-57165 | 100 µg/ml | $322.00 |